{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:49:51Z","timestamp":1784126991990,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Chemistry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Aurora-A kinase is associated with the Aurora kinase family which has been considered a striking anticancer target for the treatment of human cancers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To design, synthesize, anticancer evaluation, and docking studies of novel 2-(1-isonicotinoyl-3-phenyl-1<jats:italic>H<\/jats:italic>-pyrazol-4-yl)-3-phenylthiazolidin-4-one derivatives as Aurora-A Kinase inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>A total of 21 Pyrazole derivatives<jats:bold>P (1\u201321)<\/jats:bold>were synthesized by using the Vilsmeier Haack reagent which was characterized by FT-IR,<jats:sup>1<\/jats:sup>H NMR,<jats:sup>13<\/jats:sup>C NMR, and Mass spectroscopy. The synthesized derivatives were evaluated for their potential in vitro anticancer activity by MTT assay and Aurora-A kinase inhibition assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The cytotoxicity assay (MTT assay) showed that compound<jats:bold>P-6<\/jats:bold>exhibited potent cytotoxicity (IC<jats:sub>50<\/jats:sub>\u2009=\u20090.37\u20130.44\u00a0\u03bcM) against two cancer (HCT 116 and MCF-7) cell lines, which were comparable to the standard compound, VX-680. Compound<jats:bold>P-6<\/jats:bold>also showed inhibition of Aurora-A kinase with an IC<jats:sub>50<\/jats:sub>value of 0.11\u2009\u00b1\u20090.03\u00a0\u00b5M. A Docking study was done to compound<jats:bold>P-6<\/jats:bold>and<jats:bold>P-20<\/jats:bold>into the active site of Aurora A kinase, in order to get the probable binding model for further study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A series of 21 novel pyrazole derivatives<jats:bold>P(1\u201321)<\/jats:bold>were designed, synthesized, in vitro anticancer evaluation, and docking studies for Aurora A kinase inhibition. The results established that<jats:bold>P-6<\/jats:bold>is a prospective aspirant for the development of anticancer agents targeting Aurora-A kinase.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13065-022-00852-8","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T09:03:04Z","timestamp":1660726984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Design, synthesis, anticancer evaluation and docking studies of novel 2-(1-isonicotinoyl-3-phenyl-1H-pyrazol-4-yl)-3-phenylthiazolidin-4-one derivatives as Aurora-A kinase inhibitors"],"prefix":"10.1186","volume":"16","author":[{"given":"Meenu","family":"Beniwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navidha","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"852_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1471-4914(02)02319-5","volume":"8","author":"P Workman","year":"2002","unstructured":"Workman P, Kaye S. Translating Basic Cancer Research into new cancer therapeutics. Trends Mol Med. 2002;8:1.","journal-title":"Trends Mol Med"},{"key":"852_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nrc1529","volume":"5","author":"BA Chabner","year":"2005","unstructured":"Chabner BA, Roberts TG Jr. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5:65\u201372.","journal-title":"Nat Rev Cancer"},{"key":"852_CR3","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1007\/s00018-005-5330-x","volume":"62","author":"S Honore","year":"2005","unstructured":"Honore S, Pasquier E, Braguer D. Understanding microtubule dynamics for improved cancer therapy. Cell Mol Life Sci. 2005;62:3039\u201356.","journal-title":"Cell Mol Life Sci"},{"key":"852_CR4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1081\/CNV-200055970","volume":"23","author":"F Pellegrini","year":"2005","unstructured":"Pellegrini F, Budman DR. Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest. 2005;23:264\u201373.","journal-title":"Cancer Invest"},{"issue":"16","key":"852_CR5","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1016\/j.bmcl.2008.07.002","volume":"18","author":"JD Hansen","year":"2008","unstructured":"Hansen JD, Grina J, Newhouse B, Welch M, Topalov G, Littman N. Potent and selective pyrazole-based inhibitors of B-Rafkinase. Bioorg Med Chem Lett. 2008;18(16):4692\u20135.","journal-title":"Bioorg Med Chem Lett"},{"issue":"6","key":"852_CR6","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.bmc.2011.01.067","volume":"19","author":"MH Kim","year":"2011","unstructured":"Kim MH, Kim M, Yu H, Kim H, Yoo KH, Sim T, Hah JM. Structure based design and synthesis of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells. Bioorg Med Chem. 2011;19(6):1915\u201323.","journal-title":"Bioorg Med Chem"},{"issue":"11","key":"852_CR7","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1016\/j.bmcl.2010.12.038","volume":"21","author":"BJ Newhouse","year":"2011","unstructured":"Newhouse BJ, Hansen JD, Grina J, Welch M, Topalov G, Littman N. Non-oximepyrazole based inhibitors of B-Rafkinase. Bioorg Med Chem Lett. 2011;21(11):3488\u201392.","journal-title":"Bioorg Med Chem Lett"},{"issue":"16","key":"852_CR8","doi-asserted-by":"publisher","first-page":"4800","DOI":"10.1016\/j.bmcl.2010.06.113","volume":"20","author":"MO Duffey","year":"2010","unstructured":"Duffey MO, Adams R, Blackburn C, Chau RW, Chen S, Galvin KM. Discovery and optimization of pyrazoline compounds as B-Raf kinase inhibitors. Bioorg Med Chem Lett. 2010;20(16):4800\u20134.","journal-title":"Bioorg Med Chem Lett"},{"issue":"15","key":"852_CR9","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1016\/j.bmcl.2010.04.119","volume":"20","author":"R Ando","year":"2010","unstructured":"Ando R, Ikegami H, Sakiyama M, Ooike S, Hayashi M, Fujino Y, Abe D, Nakamura H, Mishina T, Kato H, Iwase Y. 3-Cyano-6-(5-methyl-3-pyrazoloamino) pyridines: selective Aurora A kinase inhibitors. Bioorg Med Chem Lett. 2010;20(15):4709\u201311.","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"852_CR10","first-page":"831","volume":"6","author":"KS Kumar","year":"2014","unstructured":"Kumar KS, Reddy BM, Babu VH. Synthesis of some novel 2, 4-thiazolidinedione incorporated pyrazole derivatives as anticancer agents. Int J Pharm Sci. 2014;6(2):831\u20134.","journal-title":"Int J Pharm Sci"},{"key":"852_CR11","doi-asserted-by":"publisher","first-page":"6368","DOI":"10.1021\/jm100394y","volume":"53","author":"VJ Cee","year":"2010","unstructured":"Cee VJ, Schenkel LB, Hodous BLJ. Discovery of N-(4-(3-(2-Aminopyrimidin-4-yl) pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines. Med Chem. 2010;53:6368.","journal-title":"Med Chem"},{"key":"852_CR12","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1021\/jm700954w","volume":"51","author":"AH Kishore","year":"2008","unstructured":"Kishore AH, Vedamurthy BM, Mantelingu K, Agrawal S, Reddy BA, Roy S, Rangappa KS, Kundu TK. Specific small molecule activator of Aurora Kinase A induces autophosphorylation in a cell free system. J Med Chem. 2008;51:792\u20137.","journal-title":"J Med Chem"},{"key":"852_CR13","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1021\/jm800052b","volume":"51","author":"TE Rawson","year":"2008","unstructured":"Rawson TE, R\u00fcth M, Blackwood E, Burdick D, Corson L, Dotson J, Drummond J, Fields C, Georges GJ, Goller B, Halladay J, Hunsaker T, Kleinheinz T, Krell HW, Li J. A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability. J Med Chem. 2008;51:4465\u201375.","journal-title":"J Med Chem"},{"issue":"13","key":"852_CR14","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.1021\/jm1000198","volume":"53","author":"MS Coumar","year":"2010","unstructured":"Coumar MS, Chu CY, Lin CW, Shiao HY, Ho YL, Reddy R, Lin WH, Chen CH, Peng YH, Leou JS, Lien TW, Huang CT, Fang MY, Wu SH, Wu JS, Chittimalla SK, Song JS, Hsu JT, Wu SY, Liao CC, Chao YS, Hsieh HP. Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification. J Med Chem. 2010;53(13):4980\u20138.","journal-title":"J Med Chem"},{"key":"852_CR15","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/nrm1245","volume":"4","author":"M Carmena","year":"2003","unstructured":"Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol. 2003;4:842\u201354.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"852_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/ijc.21842","volume":"119","author":"S Ulisse","year":"2006","unstructured":"Ulisse S, Delcros JG, Baldini E, Toller M, Curcio F, Giacomelli L. Expression of aurora kinases in human thyroid carcinoma cell lines and tissues. Int J Cancer. 2006;119:275\u201382.","journal-title":"Int J Cancer"},{"key":"852_CR17","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1006\/geno.1998.5522","volume":"53","author":"M Bernard","year":"1998","unstructured":"Bernard M, Sanseau P, Henry C, Couturier A, Prigent C. Cloning of STK13, a third human protein kinase related to Drosophila aurora and budding yeast Ipl1 that maps on chromosome 19q13.3-ter. Genomics. 1998;53:406\u20139.","journal-title":"Genomics"},{"key":"852_CR18","doi-asserted-by":"publisher","first-page":"7334","DOI":"10.1074\/jbc.274.11.7334","volume":"274","author":"M Kimura","year":"1999","unstructured":"Kimura M, Matsuda Y, Yoshioka T, Okano Y. Cell cycle-dependent expression and centrosome localization of a third human aurora\/Ipl1-related protein kinase, AIK3. J Biol Chem. 1999;274:7334\u201340.","journal-title":"J Biol Chem"},{"key":"852_CR19","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1091\/mbc.e10-02-0170","volume":"21","author":"KT Yang","year":"2010","unstructured":"Yang KT, Li SK, Chang CC, Tang CJ, Lin YN, Lee SC. Aurora-C kinase deficiency causes cytokinesis failure in meiosis-I and production of large polyploid oocytes in mouse. Mol Biol Cell. 2010;21:2371\u201383.","journal-title":"Mol Biol Cell"},{"key":"852_CR20","first-page":"278","volume":"5","author":"LS BavetsiasV","year":"2015","unstructured":"BavetsiasV LS. Aurora kinase inhibitors: current status and outlook. Front Oncol. 2015;5:278.","journal-title":"Front Oncol"},{"key":"852_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejmech.2017.08.045","volume":"140","author":"AC Borisa","year":"2017","unstructured":"Borisa AC, Bhatt HG. A comprehensive review on Aurora kinase: small molecule inhibitors and clinical trial studies. Eur J Med Chem. 2017;140:1\u201319.","journal-title":"Eur J Med Chem"},{"issue":"8","key":"852_CR22","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1016\/j.bmcl.2011.02.110","volume":"21","author":"A Yan","year":"2011","unstructured":"Yan A, Chong Y, Wang L, Xiaoying Hu, Wang K. Prediction of biological activity of Aurora-A kinase inhibitors by multilinear regression analysis and support vector machine. Bioorg Med Chem Lett. 2011;21(8):2238\u201343.","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"852_CR23","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1021\/jm101346r","volume":"54","author":"ME Prime","year":"2011","unstructured":"Prime ME, Courtney SM, Brookfield FA, et al. Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase. J Med Chem. 2011;54(1):312\u20139.","journal-title":"J Med Chem"},{"issue":"8","key":"852_CR24","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1016\/j.bmcl.2011.02.110","volume":"21","author":"Y Aixia","year":"2011","unstructured":"Aixia Y, Yang C, Liyu W, Xiaoying H, Kai W. Prediction of biological activity of Aurora-A kinase inhibitors by multilinear regression analysis and support vector machine. Bioorg Med Chem Lett. 2011;21(8):2238\u201343.","journal-title":"Bioorg Med Chem Lett"},{"issue":"24","key":"852_CR25","doi-asserted-by":"publisher","first-page":"7247","DOI":"10.1021\/jm060897w","volume":"49","author":"D Fancelli","year":"2006","unstructured":"Fancelli D, Moll J, Varasi M, Bravo R, Artico R, Berta D, Bindi S, Cameron A, Candiani I, Cappella P, Carpinelli P, Croci W, Forte B, Giorgini ML, Klapwijk J, Marsiglio A, Pesenti E, Rocchetti M, Roletto F, Severino D, Soncini C, Storici P, Tonani R, Zugnoni P, Vianello P. 1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: Identification of a potent aurora kinase inhibitor with a favourable antitumor kinase inhibition profile. J Med Chem. 2006;49(24):7247\u201351.","journal-title":"J Med Chem"},{"key":"852_CR26","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1016\/j.bmcl.2012.04.066","volume":"22","author":"Xi Li","year":"2012","unstructured":"Li Xi, Xiang Lu, Xing M, Yang X-H, Zhao T-T, Gong H-B, Zhu H-L. Synthesis, biological evaluation, and molecular docking studies of N-1,3-triphenyl-1H-pyrazole-4-carboxamide derivatives as anticancer agents. Bioorg Med Chem Lett. 2012;22:3589\u201393.","journal-title":"Bioorg Med Chem Lett"},{"issue":"9","key":"852_CR27","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.4155\/fmc-2017-0191","volume":"10","author":"B Poojary","year":"2018","unstructured":"Poojary B, Bhat M, Kalal BS, Swamy PMG, Kabilan S. Synthesis and evaluation of thiazolidinone\u2013pyrazole conjugates as anticancer and antimicrobial agents. Future Med Chem. 2018;10(9):1017\u201336.","journal-title":"Future Med Chem"},{"key":"852_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2174\/2213335606666190722144956","volume":"6","author":"M Beniwal","year":"2019","unstructured":"Beniwal M, Jain N. Microwave assisted synthesis, characterization and antimicrobial screening of thiazolidin-4-one substituted pyrazole derivatives. Curr Micro Chem. 2019;6:44\u201353.","journal-title":"Curr Micro Chem"},{"key":"852_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/jhet.3645","author":"M Beniwal","year":"2019","unstructured":"Beniwal M, Jain N. Novel Approach for Rapid and Efficient Synthesis of 2-(3-(4-Aryl)-1-isonicotinoyl-4,5-dihydro-1H-pyrazol-4-yl)-3-phenylthiazolidin-4-one derivatives and screened their antimicrobial activity. J Heterocyclic Chem. 2019. https:\/\/doi.org\/10.1002\/jhet.3645.","journal-title":"J Heterocyclic Chem"},{"key":"852_CR30","unstructured":"Pavia DL, Lampman GM, Kriz GS. Introduction to spectroscopy, 3rd edition, page no. 13\u2013189."},{"key":"852_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55\u201363.","journal-title":"J Immunol Methods"},{"key":"852_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1387-2656(05)11004-7","volume":"11","author":"MV Berridge","year":"2005","unstructured":"Berridge MV, Herst PM, Tan AS. Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev. 2005;11:127\u201352.","journal-title":"Biotechnol Annu Rev"},{"key":"852_CR33","first-page":"237","volume":"731","author":"J VanMeerloo","year":"2011","unstructured":"VanMeerloo J, Kaspers GJL, Cloos J. Cell sensitivity assays: the MTT assay methods. Mol Biol. 2011;731:237\u201345.","journal-title":"Mol Biol"},{"key":"852_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3329\/bjp.v12i2.30892","volume":"12","author":"A Bahuguna","year":"2017","unstructured":"Bahuguna A, Khan I, Bajpai VK, Kang SC. MTT assay to evaluate the cytotoxic potential of a drug. Bangladesh J Pharmacol. 2017;12:115\u20138. https:\/\/doi.org\/10.3329\/bjp.v12i2.30892.","journal-title":"Bangladesh J Pharmacol"},{"key":"852_CR35","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ab.2005.01.055","volume":"340","author":"C Bernal","year":"2005","unstructured":"Bernal C, Mendez E, Terencio J, Boronat A, Imperial S. A spectrophotometric assay for the determination of 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase activity. J Anal Biochem. 2005;340:245.","journal-title":"J Anal Biochem"},{"key":"852_CR36","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1088\/2043-6262\/7\/3\/035018","volume":"7","author":"TT Duong","year":"2016","unstructured":"Duong TT, Phuong T, Thi HY, Dac TN, Hoai NN, Khanh VB, Nhung H. In vitro evaluation of Aurora kinase inhibitor\u2014VX680\u2014in formulation of PLA-TPGS nanoparticles. Adv Nat Sci Nanosci Nanotechnol. 2016;7:2043\u20136262.","journal-title":"Adv Nat Sci Nanosci Nanotechnol"},{"key":"852_CR37","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1021\/jm049076m","volume":"48","author":"AD Cameron","year":"2005","unstructured":"Cameron AD, Izzo G, Sagliano A, Rusconi L, Storici P, Fancelli D, Berta D, Bindi S, Catana C, Forte B, Giordano P, Mantegani S, Meroni M, Moll J, Pittala V, Severino D, Tonani R, Varasi M, Vulpetti A, Vianello P. Aurora-2 T287D T288D complexed with PHA-680632 (2bmc). J Med Chem. 2005;48:3080.","journal-title":"J Med Chem"},{"issue":"2","key":"852_CR38","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Ollson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem. 2010;31(2):455\u201361.","journal-title":"J Comput Chem"},{"issue":"16","key":"852_CR39","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris GM, Huey R, Lindstrom W. AutoDock and AutoDockTools: automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785\u201391.","journal-title":"J Comput Chem"}],"container-title":["BMC Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-022-00852-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13065-022-00852-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-022-00852-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T21:36:00Z","timestamp":1700948160000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcchem.biomedcentral.com\/articles\/10.1186\/s13065-022-00852-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["852"],"URL":"https:\/\/doi.org\/10.1186\/s13065-022-00852-8","relation":{},"ISSN":["2661-801X"],"issn-type":[{"value":"2661-801X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]},"assertion":[{"value":"30 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest regarding the publication of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}